Author Archive

— Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery — Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® […]

Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international […]

Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development […]

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based […]

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference Ghent, Belgium, 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Boston, MA. Confo Therapeutics is also […]

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in […]

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBody™-enabled GPCRs with DyNAbind’s Dynamic […]

Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and […]

Confo Therapeutics raises €30 million in Series A financing Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30 million ($33.4 million) Series A financing. The […]

Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine Ghent, Belgium, 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, […]